Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir

MT Newswires Live

Apr 27

Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.

It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.

It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.

Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.

Its shares were up 1% in recent trading on Monday.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.itiger.com/news/2630351272"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2630351272\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2630351272?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-04-27 13:07","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2630351272","market":"nz","top_or_hot":-1,"title":"Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir","media":"MT Newswires Live","content":"<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>","source":"mtnewswires_news","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Island Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nIsland Pharmaceuticals Works Alongside USAMRIID to Advance Clinical Development For Galidesivir\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1092851196\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">MT Newswires Live </p>\n<p class=\"h-time\">2026-04-27 13:07</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html><body><p> <a href=\"https://laohu8.com/S/ILA.AU\">Island Pharmaceuticals</a>' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.</p><p>It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.</p><p>It worked alongside Todd <a href=\"https://laohu8.com/S/MSTR\">Strategy</a> Group and MC2 to advance industry engagement initiatives in the US during the March quarter.</p><p>Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.</p><p>Its shares were up 1% in recent trading on Monday.</p></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK7096","symbol_name":"制药","start_time":0,"source_url":"https://www.mtnewswires.com/","article_id":"2630351272","we_media_id":"1092851196","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2630351272","pubTimestamp":1777266438,"columns":[],"sourceInfo":{"source_id":"mtnewswires_news","name":"MT Newswires"},"weMediaInfo":{"media_name":"MT Newswires Live","introduction":"The most recognized names in North America, Europe and Asia rely on MT Newswires to power their applications. Better news, better service, better price.","home_visible":1,"id":"1092851196","head_image":"https://community-static.tradeup.com/news/3002d84abbd5ace3c99397c7f95b8d4e"},"summary":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phas","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK7096":"制药","ILA.AU":"ISLAND PHARMACEUTICALS LTD"},"translate_title":"Island Pharmaceuticals与USAMRIID合作推进加利德西韦的临床开发","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"ILA.AU":1},"content_text":"Island Pharmaceuticals' (ASX:ILA) work alongside the US Army Medical Research Institute of Infectious Diseases (USAMRIID) and Texas Biomedical Research Institute is well progressed, with the next phase of clinical development for its Galidesivir drug candidate expected to start shortly, according to a Monday Australian bourse filing.It received around a AU$143,000 refund under the Australian Government's research and development tax incentive for the fiscal year 2025. The refund relates to eligible expenditure associated with the ongoing development of ISLA-101.It worked alongside Todd Strategy Group and MC2 to advance industry engagement initiatives in the US during the March quarter.Galidesivir is a clinical-stage antiviral molecule with broad-spectrum activity against over 20 RNA viruses, including Ebola, Marburg, MERS, Zika, and Yellow fever, the filing added.Its shares were up 1% in recent trading on Monday.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"corporation","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"}}}